Publications by authors named "John Vernon"

Claim this Profile
V
Vertebral venous system abnormalities identified with magnetic resonance imaging in sighthounds.
John C Vernon, Alexane Durand, Julien Guevar, Roberto José-López, Gawain Hammond

Vet Radiol Ultrasound· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the Confusion Assessment Method for the Intensive Care Unit in older emergency department patients.
Jin H Han, Amanda Wilson, Amy J Graves, Ayumi Shintani, John F Schnelle, John Vernon

Acad Emerg Med· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring the patient health, societal and economic benefits of US pediatric therapeutics legislation.
John A Vernon, Scott H Shortenhaus, Mark H Mayer, Albert J Allen, Joseph H Golec

Paediatr Drugs· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The case for less, not more, US FDA regulation.
John A Vernon, Joseph H Golec

Pharmacoeconomics· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correctly measuring drug development risk: a public policy imperative.
John A Vernon, Joseph H Golec

Expert Rev Pharmacoecon Outcomes Res· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness regulations and pharmaceutical innovation.
John A Vernon, Joseph H Golec, J Stedman Stevens

Pharmacoeconomics· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms.
Joseph Golec, John A Vernon

Pharmacoeconomics· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug development costs when financial risk is measured using the Fama-French three-factor model.
John A Vernon, Joseph H Golec, Joseph A Dimasi

Health Econ· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of gender differences in health among the elderly in Latin America.
Antonio J Trujillo, Thomas A Mroz, Claudia Piras, John A Vernon, Gustavo Angeles

World Health Popul· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic opportunities and challenges for pharmacogenomics.
Patricia A Deverka, John Vernon, Howard L McLeod

Annu Rev Pharmacol Toxicol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Financial risk of the biotech industry versus the pharmaceutical industry.
Joseph Golec, John A Vernon

Appl Health Econ Health Policy· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic evaluation and cost-effectiveness thresholds: signals to firms and implications for R & D investment and innovation.
John A Vernon, Robert Goldberg, Joseph Golec

Pharmacoeconomics· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care.
Tejinder K Rakhra-Burris, J Todd Auman, Patricia Deverka, Lynn G Dressler, James P Evans, John A Vernon

Pharmacogenomics· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Social welfare and adolescent vaccination programs in the United States: the economic opportunities for a systematic expansion.
John A Vernon, Michael Payette, Abhishek Chatterjee

Soc Work Public Health· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The future costs, risks and rewards of drug development: the economics of pharmacogenomics.
Joseph Cook, Graeme Hunter, John A Vernon

Pharmacoeconomics· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Race and health disparities among seniors in urban areas in Brazil.
Antonio J Trujillo, John A Vernon, Laura Rodriguez Wong, Gustavo Angeles

J Aging Health· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring US pharmaceutical industry R&D spending.
Joseph Golec, John Vernon

Pharmacoeconomics· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considering the economic principles of pharmaceutical R&D.
John A Vernon

Expert Opin Drug Discov· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmaceutical risk-sharing agreements.
Joseph P Cook, John A Vernon, Richard Manning

Pharmacoeconomics· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ownership form and consumer welfare: evidence from the nursing home industry.
Rexford E Santerre, John A Vernon

Inquiry· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Future of drug development: the economics of pharmacogenomics.
John A Vernon, Keener Hughen, Joseph H Golec

Expert Rev Clin Pharmacol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives on dynamic optimisation and control theory in treating hyperlipidaemia.
John A Vernon

Pharmacoeconomics· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter from the Commissioner's Office at the US FDA.
John A Vernon

Pharmacoeconomics· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter from the Commissioner's office at the US FDA.
John A Vernon

Pharmacoeconomics· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter from the Commissioner's Office at the US FDA.
John A Vernon

Pharmacoeconomics· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis